Clinical Trial

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose escalation part (Phase I) and an expansion part (Phase Ⅱ)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-06; most recent amendment 2024-11-19.
Status change: Not Yet Recruiting → Recruiting 2023-08-09
Trial Details
NCT Number NCT05806099
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions Non-Hodgkin's Lymphoma
Enrollment 132 participants
Start Date 2023-06-28
Primary Completion 2025-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2024-11-20